[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing Minova Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100650573","phase-1-a-study-of-mi226-injection-for-abdominal-fat-accumulation-100650573",false,"NCT07749742","A Study of MI226 Injection for Abdominal Fat Accumulation","A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of MI226 Injection in Subjects With Abdominal Fat Accumulation","Inclusion Criteria:\n\n* Aged ≥18 and \\\u003C65 years at the time of screening.\n* Male body weight ≥50 kg, female body weight ≥45 kg, and body mass index (BMI) between 19.0 kg\u002Fm² and 37.0 kg\u002Fm² (inclusive).\n* Presence of clinically appreciable abdominal fat accumulation, as assessed by the Clinical Photonumeric Rating Scale (CPnS) with a score of ≥2, and judged by the investigator as sufficient to accommodate the planned number of injections per assigned cohort.\n* Willingness to use effective contraceptive measures and to refrain from sperm\u002Fegg donation from the screening period until 3 months after the last dose of study drug; and no pregnancy plan during this period.\n* Ability to understand and voluntarily participate in the study, agree to comply with all study requirements, and provide written informed consent prior to any study-related procedures.\n\nExclusion Criteria:\n\n* Presence of any medical or physical condition that, in the judgment of the investigator, may interfere with the evaluation of efficacy or safety (e.g., uncontrolled hypertension, and respiratory, cardiovascular, hepatic, neurological, or thyroid diseases).\n* Presence of adipose tissue volume deficiency (e.g., post-traumatic) or immune-mediated lipodystrophy syndromes, including: generalized lipodystrophy (e.g., juvenile dermatomyositis-associated), partial lipodystrophy (e.g., Barraquer-Simons syndrome), or HIV-associated lipodystrophy.\n* History of or current clinically relevant skin disease that, in the judgment of the investigator, may affect the assessment of the injection site, or presence of keloid tendency (history of predisposition to hypertrophic scarring or keloid formation).\n* History of hypersensitivity (allergy to at least 2 substances) or known allergy to any component of the study drug.\n* Serious medical or psychiatric illness that, in the judgment of the investigator, may affect the study results or compromise participant compliance.\n* Restricted mobility, history of deep vein thrombosis or pulmonary embolism, or major surgery (within the past 3 months), or long-term hospitalization.\n* Known bleeding disorders, or use of medications that may increase the risk of post-injection bleeding (e.g., anticoagulant or antiplatelet therapy that cannot be safely discontinued) within 4 weeks prior to screening.\n* Females of childbearing potential who are pregnant, lactating, planning to become pregnant, or not using reliable contraceptive measures, and who are unwilling to use reliable contraception during the study (e.g., transdermal patches, intrauterine device\u002Fsystem \\[IUD\u002FIUS\\], condoms, abstinence, or partner vasectomy).\n* Any other condition that, in the investigator's opinion, may significantly increase the participant's risk, confound the study results, or substantially interfere with the participant's participation in the study.","ALL","18 Years","65 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1, randomized, double-blind (with open-label sentinel cohorts), placebo-controlled, single-ascending-dose study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of MI226 Injection in participants with abdominal fat accumulation.",[27],"Abdominal Fat",[27,29],"MI226 Injection","RECRUITING","2026-08-04",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":34},"2026-07-28",{"date":38,"type":21},"2027-03",{"name":40,"class":41},"Nanjing Minova Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100648613","phase-3-a-study-of-mi078-for-postpartum-depression-100648613","NCT07721961","A Study of MI078 for Postpartum Depression","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Clinical Trial of MI078 Capsules for the Treatment of Patients With Postpartum Depression","Inclusion Criteria:\n\n* Female patients aged 18-45 years (inclusive) with a body mass index (BMI) of 18.5-37.0 kg\u002Fm² (inclusive).\n* Based on the investigator's clinical evaluation, the participant meets the diagnostic criteria for Major Depressive Disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by clinical assessment and the Mini-International Neuropsychiatric Interview (M.I.N.I.), with onset of depression between gestational week 28 and 4 weeks postpartum (inclusive).\n* Within 12 months postpartum at baseline.\n* Total score ≥26 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at both screening and baseline.\n* Understand and voluntarily participate in this trial, agree to comply with all study requirements, and provide written informed consent prior to any study-specific procedures.\n* Able to communicate well with the investigator, willing and able to comply with lifestyle restrictions or requirements specified in the protocol, and capable of completing the trial as required.\n\nExclusion Criteria:\n\n* Currently meeting diagnostic criteria for other DSM-5 psychiatric disorders, as assessed by the investigator.\n* History of bipolar disorder, schizophrenia, and\u002For schizoaffective disorder.\n* Reduction in HAM-D17 total score from screening to baseline ≥25%.\n* Presence of suicidal ideation\u002Fintent, or HAM-D17 Item 3 (suicide) score \\>3, or a \"yes\" response to Item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation in the past 6 months at baseline, or a history of suicidal behavior within 1 year.\n* Meeting diagnostic criteria for treatment-resistant depression.\n* Continuous use of therapeutic doses of antidepressants for more than 14 days during the current episode.\n* Discontinuation of psychotropic medications for less than 5 half-lives prior to the first dose of study drug.\n* Need for concomitant use of other psychoactive drugs during the treatment period, including antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics (excluding non-benzodiazepines).\n* Discontinuation of strong CYP3A4 inducers or inhibitors for less than 5 half-lives prior to the first dose of study drug.\n* Receipt of systematic psychotherapy (e.g., interpersonal therapy, psychodynamic therapy, cognitive-behavioral therapy) or psychiatric-related acupuncture within 1 week prior to the first dose, or planned receipt of such treatments during the trial.\n* Receipt of other physical treatments for psychiatric disorders (e.g., modified electroconvulsive therapy, transcranial magnetic stimulation, psychiatric-related laser therapy, vagus nerve stimulation, deep brain stimulation, light therapy) within 1 month prior to screening.\n* Presence of severe or unstable cardiovascular, hepatic, renal, hematological, endocrine (e.g., uncontrolled hyper- or hypothyroidism), neurological (e.g., epilepsy, Parkinson's disease, multiple sclerosis, Huntington's disease, history of seizure disorder \\[except single febrile seizure in childhood\\]), gastrointestinal (e.g., history of gastrointestinal disease or surgery that may interfere with drug absorption, distribution, metabolism, or excretion), or other systemic or organ diseases, as judged by the investigator.\n* History of malignancy within 1 year prior to screening.\n* Participation in another drug trial within 3 months prior to screening, or participation in a medical device trial within 1 month prior to screening (defined as having received investigational drug or device treatment).\n* Major surgery (excluding cesarean section) within 1 month prior to screening, or planned surgery during the trial period.\n* History of hypersensitivity (allergy to at least 2 substances) or known allergy to progesterone.\n* Positive pregnancy test at screening or baseline (for participants who are 4 weeks postpartum, a positive result requires retesting), or unwillingness to use effective contraception throughout the trial and for at least 3 months after the last dose of study drug, or plans for oocyte donation during this period.\n* Clinically significant abnormal 12-lead electrocardiogram (ECG) or laboratory findings at screening or baseline that, in the investigator's opinion, may affect the trial, including but not limited to alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2× upper limit of normal (ULN), or serum creatinine \\>1.5× ULN.\n* Currently breastfeeding and unwilling to discontinue breastfeeding during the treatment period and for 7 days after the last dose.\n* Any physical\u002Fpsychological illness or condition that, in the investigator's opinion, may increase the risk of the trial, affect compliance with the protocol, or interfere with the completion of the study, or any other condition that the investigator deems unsuitable for participation in this trial.","FEMALE","45 Years",{"count":53,"type":21},200,[55],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled trial consisting of an experimental drug group and a placebo group, each enrolling 100 participants. The objective of this study is to assess the efficacy and safety of MI078 capsules for the treatment of postpartum depression.",[58],"Postpartum Depression (PPD)","2026-07-18",{"date":61,"type":34},"2026-07-23",{"date":63,"type":34},"2026-07-10",{"date":65,"type":21},"2027-12",{"name":40,"class":41},36,""]